Phase 4 N=40 Namenda (Memantine) for Non-motor Symptoms in Parkinson's Disease
Parkinson's Disease
Primary: Unified Parkinson Disease Rating Scale (UPDRS). — 12; 12; 10; 10 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=9 Effect of Exercise in Parkinsonism
Parkinson's Disease · Drug-induced Parkinsonism
Primary: Change in Dopamine Transporter Imaging — 4.6; -15.9 % change in arbitrary intensity units
N/A N=37 Amyloidopathy, Cholinopathy, Dopamine Responsiveness and Freezing of Gait in PD
Parkinson's Disease
Primary: L-DOPA Insensitivity — 5 Participants — p=0.00468
N/A N=11 The Role of Cerebellar Hyperactivity in Parkinson's Disease
Parkinson's Disease
Primary: Change in Gait Speed- Sham_On — -0.0185 meters per second (m/s)
N/A N=9 Bracing for Walking in Parkinson's Disease
Gait Disorders, Neurologic · Parkinson Disease
Primary: Change in Gait Capacity as Assessed b 6-Minute Walk Test — 235.7; 150.0 Feet
Phase 3 N=172 A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients
Parkinsonian Syndrome · Parkinson Disease(PD) · Multiple System Atrophy (MSA)
Primary: Sensitivity Analysis of the Blinded Independent Read of DaTSCAN™ SPECT Images — 0.851; 0.865; 0.919 ratio
N/A N=51 Physiological Effects of Nutritional Support in Patients With Parkinson's Disease
Parkinson Disease · Idiopathic Parkinson Disease
Primary: Distribution Volume Ratio — 2.65; 2.70; 2.96; 2.74 Distribution volume ratios — p=0.05
Phase 2 N=90 Image Parkinson's Disease Progression Study
Parkinson's Disease
Primary: Change in Free-water Accumulation in the Substantia Nigra — 0.0009; 0.0041 arbitrary units (A.U.s)
Early Phase 1 N=54 Cognitive Rehabilitation in Parkinson's Disease
Parkinson's Disease
Primary: Reaction Time and Variability for Movement Task — 1013.858333; 994.94875; 979.2450877; 910.9120833 milliseconds
N/A N=2,448 First Presentation of Parkinson Disease Patients to Neurologist
Parkinson Disease
Primary: Number of De-novo Patients in Whom Monotherapy With Mirapexin® Could be Successfully Initiated — 403; 323; 73; 15 Participants
Phase 4 N=21 The Effect of Donepezil on Gait and Balance in Parkinson's Disease
Parkinson's Disease
Primary: Sensory Organization Test - Composite Score — 7.7; 0.6 score on a scale
N/A N=57 Aerobic Exercise in Parkinson's Disease
Parkinson's Disease
Primary: Change in MDS-UPDRS Part III Motor (OFF) Score — 0.44; -2.96 score on scale — p=>0.05
Phase 2 N=25 Transcranial Direct Current Stimulation to Treat Symptoms of Parkinson's Disease
Parkinson Disease
Primary: Gait Speed Before and After Real and Sham tDCS. — 8.7; 8.6; 9.7; 9.5 Seconds
Phase 2 N=253 Dyskinesia in Parkinson's Disease (Study P04501)
Parkinson Disease · Movement Disorders · Central Nervous System Diseases
Primary: Change From Baseline to Endpoint of 12 Weeks in the 3-day Average of Awake Time Per Day Spent in the "Off" State — -0.4; -1.3; -1.6; -1.7 hours/day — p=0.753
N/A N=45 Nintendo WII and Exercises at Rehabilitation of Individuals With Parkinson's Disease
Parkinson Disease
Primary: Berg Balance Scale — 40.5; 43.9; 41.6; 45.6 Score on a scale
N/A N=61 Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP)
Progressive Supranuclear Palsy
Primary: Efficacy of Coenzyme Q10 (Unified Parkinson's Disease Rating Scale [UPDRS] AND Progressive Supranuclear Palsy Rating Scale [PSPRS]) — 5.9; 11.8; 11.5; 12.8 units on a…
N/A N=30 The Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Early Parkinson's Disease
Idiopathic Parkinson's Disease
Primary: Longitudinal Change of Brain Network Activity — 0.41; 0.61; 2.21; 3.61 Z-score in PDRP — p=0.84
Phase 4 N=296 Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive Symptoms
Parkinson Disease · Depression
Primary: Change From Baseline in the Beck Depression Inventory-Version 1A (BDI-IA) Total Score at Week 12 — -4; -5.9 Score on scale — p=0.0103
N/A N=60 Evaluation of a Millimeter Wave Emission Bracelet for Improving Parkinson's Disease Symptoms
Parkinson Disease
Primary: Assessment of the Effectiveness of Two Months of Use of the Remedee Endorphin Band Medical Device in Improving Motor Disorders in Patients With Parkinson's Disease — 6…
Phase 3 N=40 Effect of Levodopa on Cardiovascular Autonomic Function in Parkinson's Disease
Parkinson Disease · Orthostatic Hypotension
Primary: Change in Systolic Blood Pressure From Supine to Tilt at 3 Minutes — -24.22; -20.32 mmHg
N/A N=29 Physical Therapy and Deep Brain Stimulation in Parkinson Disease
Parkinson Disease
Primary: Number of Participants With Treatment-Emergent Adverse Events [Safety & Tolerability] — 1 Participants
Phase 4 N=5 Mirabegron in Parkinson Disease and Impaired Cognition
Parkinson Disease · Overactive Bladder · Impaired Cognition
Primary: Change in Montreal Cognitive Assessment Total Score — 1.5; 2 units on a scale
N/A N=221 Evaluation of Clinical Decision Support System-mPDia for Neurodegenerative Parkinsonism Using MRI Images
Diagnoses Disease
Primary: Sensitivity of mPDia for the Diagnosis of Neurodegenerative Parkinsonism — 94.30 percentage
Phase 4 N=19 Vigor and the LDR in Parkinson Disease
Parkinson Disease
Primary: Tapping Speed Task - Experiment 1 — 110.52; 128.89; 138.43; 145.86 taps/min
N/A N=87 Usefulness of α-synuclein as a Marker for Early Diagnosis of Parkinson's Disease in Skin Biopsy.
Parkinson Disease · Parkinsonian Disorders
Primary: Demonstrate the Presence of Alpha-Synuclein Inclusions in the Skin of Parkinson's Disease and Compare With an Atypical Parkinsonism Group and With a Healthy Control…
Phase 2 N=22 A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's Disease
Parkinson's Disease
Primary: Number of Participants With Serious Adverse Events — 0; 0; 0 Participants
N/A N=32 Prism Adaptation Treatment of Parkinson's Disease
Parkinson
Primary: Change in Postural Control - Reaction Time on the Limits of Stability Test (Smart Equitest Balance Master System) — 0.09; -0.02 Seconds
Phase 3 N=77 Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease
Overactive Bladder · Parkinson Disease
Primary: ICIQ-OAB Questionnaire — 5.5; 5.8 score on a scale
N/A N=15 Neural Signatures of Parkinson's Disease
Parkinson's Disease
Primary: Change in Resting State Beta Band Power Over Time — -0.28 regression beta coefficient — p=0.038
Phase 2 N=94 GM1 Ganglioside Effects on Parkinson's Disease
Parkinson Disease
Primary: Change in Unified Parkinson's Disease Rating Scale (UPDRS) (Part III) Motor Score From Baseline to Week 24 Assessed Off Medication. — -3.57; 1.85 Scores on a scale…